List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11933509/publications.pdf

Version: 2024-02-01

429 papers	25,702 citations	5876 81 h-index	11030 137 g-index
435 all docs	435 docs citations	435 times ranked	18595 citing authors

#	Article	IF	Citations
1	Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955.	6.3	2,182
2	Chemotherapyâ€induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437.	157.7	547
3	Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews Neurology, 2011, 7, 639-649.	4.9	503
4	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	9.4	494
5	Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322.	4.9	454
6	Multiple measures of axonal excitability: A new approach in clinical testing. , 2000, 23, 399-409.		412
7	Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-1550.	3.7	391
8	Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, The, 2009, 8, 94-109.	4.9	391
9	Excitability of human axons. Clinical Neurophysiology, 2001, 112, 1575-1585.	0.7	384
10	Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 973-985.	0.9	320
11	Strength-duration properties of human peripheral nerve. Brain, 1996, 119, 439-447.	3.7	316
12	Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurology, The, 2016, 15, 1182-1194.	4.9	301
13	The frontotemporal dementia-motor neuron disease continuum. Lancet, The, 2016, 388, 919-931.	6.3	294
14	Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-2446.	3.7	284
15	Motor Neuron dysfunction in frontotemporal dementia. Brain, 2011, 134, 2582-2594.	3.7	271
16	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	0.7	268
17	Guillain-BarrÃ© syndrome: An update. Journal of Clinical Neuroscience, 2009, 16, 733-741.	0.8	224
18	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	9.4	223

#	Article	IF	Citations
19	Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1161-1170.	0.9	213
20	Neurotoxic marine poisoning. Lancet Neurology, The, 2005, 4, 219-228.	4.9	205
21	FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 639-645.	0.9	205
22	Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 2009, 132, 2712-2723.	3.7	198
23	Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle and Nerve, 2005, 32, 51-60.	1.0	194
24	Activity-dependent hyperpolarization of human motor axons produced by natural activity. Journal of Physiology, 1998, 507, 919-925.	1.3	191
25	Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in Neurosciences, 2014, 37, 433-442.	4.2	186
26	Axonal excitability properties in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2006, 117, 1458-1466.	0.7	177
27	TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95.	0.9	174
28	Uremic neuropathy: Clinical features and new pathophysiological insights. Muscle and Nerve, 2007, 35, 273-290.	1.0	173
29	Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. Oncologist, 2011, 16, 708-716.	1.9	171
30	Consensus for experimental design in electromyography (CEDE) project: Amplitude normalization matrix. Journal of Electromyography and Kinesiology, 2020, 53, 102438.	0.7	170
31	Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain, 2002, 125, 664-675.	3.7	169
32	Grey and White Matter Changes across the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Continuum. PLoS ONE, 2012, 7, e43993.	1.1	168
33	How common are behavioural changes in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 45-51.	2.3	165
34	Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nature Reviews Neurology, 2016, 12, 651-661.	4.9	165
35	Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, The, 2015, 14, 478-484.	4.9	164
36	Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 2006, 33, 477-486.	1.0	162

#	Article	IF	Citations
37	Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Annals of Neurology, 2005, 57, 339-348.	2.8	159
38	Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 2019, 15, 540-555.	4.9	159
39	Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 2017, 81, 355-368.	2.8	157
40	Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. Journal of Clinical Oncology, 2009, 27, 1243-1249.	0.8	153
41	Cortical influences drive amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 917-924.	0.9	152
42	Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118.	4.9	152
43	Kidneyâ€“brain crosstalk in the acute and chronic setting. Nature Reviews Nephrology, 2015, 11, 707-719.	4.1	151
44	Neurological complications of chronic kidney disease. Nature Reviews Neurology, 2009, 5, 542-551.	4.9	148
45	Axonal ion channels from bench to bedside: A translational neuroscience perspective. Progress in Neurobiology, 2009, 89, 288-313.	2.8	144
46	Frontotemporal Dementia Associated With theC9ORF72Mutation. JAMA Neurology, 2014, 71, 331.	4.5	144
47	Clinical evaluation of excitability measures in sensory nerve. Muscle and Nerve, 2001, 24, 883-892.	1.0	141
48	Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2015, 126, 803-809.	0.7	140
49	Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 2014, 76, 643-657.	2.8	133
50	Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479.	4.9	130
51	Differences in activity-dependent hyperpolarization in human sensory and motor axons. Journal of Physiology, 2004, 558, 341-349.	1.3	129
52	Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 102-109.	2.3	124
53	Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493.	4.9	124
54	Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370.	3.7	123

#	Article	IF	Citations
55	Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain, 2002, 125, 1366-1378.	3.7	122
56	Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 2011, 122, 1860-1866.	0.7	122
57	Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 245-250.	2.3	121
58	Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurology, The, 2016, 15, 332-342.	4.9	120
59	Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377.	0.9	118
60	Altered nerve excitability properties in established diabetic neuropathy. Brain, 2005, 128, 1178-1187.	3.7	114
61	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534.	3.7	114
62	The Puzzling Case of Hyperexcitability in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurology		

#	Article	IF	Citations
73	Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2013, 124, 410-416.	0.7	97
74	Axonal changes in spinal cord injured patients distal to the site of injury. Brain, 2006, 130, 985-994.	3.7	96
75	Neuropsychiatric changes precede classic motor symptoms in ALS and do not affect survival. Neurology, 2014, 82, 149-155.	1.5	95
76	Consensus for experimental design in electromyography (CEDE) project: Electrode selection matrix. Journal of Electromyography and Kinesiology, 2019, 48, 128-144.	0.7	95
77	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain, 2015, 138, 3110-3122.	3.7	94
78	Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 2012, 20, 2959-2967.	1.0	93
79	Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483.	0.9	93
80	Pathophysiological insights into ALS with C9ORF72 expansions. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 931-935.	0.9	89
81	Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics, 2017, 14, 91-106.	2.1	89
82	Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain, 2008, 131, 1209-1216.	3.7	87
83	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2016, 127, 2643-2660.	0.7	87
84	Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 222-227.	0.9	86
85	Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. Clinical Neurophysiology, 2021, 132, 2568-2607.	0.7	85
86	Oxaliplatin and Axonal Na+ Channel Function In vivo. Clinical Cancer Research, 2006, 12, 4481-4484.	3.2	82
87	Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PLoS ONE, 2014, 9, e105632.	1.1	79
88	Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186.	4.5	79
89	Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520.	1.5	76
90	Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 773-779.	0.9	76

#	Article	IF	Citations
91	Nerve function and dysfunction in acute intermittent porphyria. Brain, 2008, 131, 2510-2519.	3.7	75
92	Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87124.	1.1	75
93	Psychiatric disorders in C9orf72 kindreds. Neurology, 2018, 91, e1498-e1507.	1.5	75
94	Assessment of disease progression in motor neuron disease. Lancet Neurology, The, 2005, 4, 229-238.	4.9	74
95	Cortical excitability testing distinguishes Kennedyâ€™s disease from amyotrophic lateral sclerosis. Clinical Neurophysiology, 2008, 119, 1088-1096.	0.7	74
96	Cortical Function in Asymptomatic Carriers and Patients WithC9orf72Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 1268.	4.5	74
97	Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691.	0.7	74
98	Eating behavior in frontotemporal dementia. Neurology, 2015, 85, 1310-1317.	1.5	72
99	Physiological changes in neurodegeneration â€” mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271.	4.9	72
100	Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 220, 177-182.	2.0	71
101	Conduction block in carpal tunnel syndrome. Brain, 1999, 122, 933-941.	3.7	69
102	Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxelâ€induced neuropathy. Muscle and Nerve, 2011, 43, 367-374.	1.0	69
103	Diagnostic Utility of Gold Coast Criteria in <scp>Amyotrophic Lateral Sclerosis</scp>. Annals of Neurology, 2021, 89, 979-986.	2.8	68
104	The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Research, 2009, 1273, 39-47.	1.1	67
105	Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. Neurology, 2018, 91, e1669-e1676.	1.5	67
106	Temperature dependence of excitability indices of human cutaneous afferents. , 1999, 22, 51-60.		66
107	What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Preference and Adherence, 2012, 6, 829.	0.8	65
108	Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Medicine Reviews, 2016, 26, 33-42.	3.8	65

#	Article	IF	Citations
109	INSPIRATIonAL â€“ INSPIRAtory muscle training in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2009, 10, 384-392.	2.3	64
110	FTD and ALSâ€”translating mouse studies into clinical trials. Nature Reviews Neurology, 2015, 11, 360-366.	4.9	64
111	Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Neurology, 2011, 68, 862.	4.9	63
112	Guillain-Barre syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 907-913.	0.9	63
113	Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 595-604.	1.1	63
114	Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323.	0.7	63
115	Puffer fish poisoning: a potentially lifeâ€threatening condition. Medical Journal of Australia, 2002, 177, 650-653.	0.8	62
116	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	4.9	62
117	Dose Effects of Oxaliplatin on Persistent and Transient Na+ Conductances and the Development of Neurotoxicity. PLoS ONE, 2011, 6, e18469.	1.1	61
118	The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. NeuroImage: Clinical, 2017, 13, 439-445.	1.4	60
119	Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493.	1.0	59
120	Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 580-588.	1.1	58
121	Assessment of nerve excitability in toxic and metabolic neuropathies. Journal of the Peripheral Nervous System, 2008, 13, 7-26.	1.4	57
122	Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain, 2005, 128, 1841-1846.	3.7	54
123	Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1202-1208.	0.9	54
124	A novel tool to detect behavioural symptoms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 298-304.	1.1	53
125	Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1569-1577.	2.2	53
126	Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 283-289.	2.3	52

#	Article	IF	Citations
127	What are the roles of carers in decision-making for amyotrophic lateral sclerosis multidisciplinary care?. Patient Preference and Adherence, 2013, 7, 171.	0.8	52
128	Utility of threshold tracking transcranial magnetic stimulation in ALS. Clinical Neurophysiology Practice, 2018, 3, 164-172.	0.6	51
129	Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175.	0.7	50
130	Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 481-487.	1.1	48
131	Systemic metabolism in frontotemporal dementia. Neurology, 2014, 83, 1812-1818.	1.5	48
132	Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics, 2015, 15, 509-522.	1.4	48
133	Multifocal motor neuropathy: controversies and priorities. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 140-148.	0.9	48
134	The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 281-293.	1.4	48
135	Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2021, 58, 87-95.	1.5	48
136	Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 33-38.	2.3	47
137	FOSMN syndrome. Neurology, 2012, 79, 73-79.	1.5	47
138	Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 1424-1432.	1.8	47
139	Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. Journal of Alzheimer's Disease, 2017, 61, 773-783.	1.2	47
140	Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 315-318.	1.1	46
141	Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 2014, 125, 179-185.	0.7	46
142	Peripheral nerve diffusion tensor imaging is reliable and reproducible. Journal of Magnetic Resonance Imaging, 2016, 43, 962-969.	1.9	46
143	Diagnostic criteria in amyotrophic lateral sclerosis. Neurology, 2016, 87, 684-690.	1.5	46
144	Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1011-1020.	0.9	45

#	Article	IF	Citations
145	Cortical hyperexcitability evolves with disease progression in ALS. Annals of Clinical and Translational Neurology, 2020, 7, 733-741.	1.7	45
146	ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 2014, 125, 186-193.	0.7	44
147	Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 39-46.	1.1	44
148	Nerve excitability properties in lower-limb motor axons: Evidence for a length-dependent gradient. Muscle and Nerve, 2004, 29, 645-655.	1.0	43
149	Energy expenditure in frontotemporal dementia: a behavioural and imaging study. Brain, 2017, 140, 171-183.	3.7	43
150	Axonal Excitability in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 78-90.	2.1	43
151	Review: Neuromuscular Disease in the Dialysis Patient: An Update for the Nephrologist. Seminars in Dialysis, 2009, 22, 267-278.	0.7	42
152	Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2460-2467.	0.7	42
153	Quantitative ultrasound of denervated hand muscles. Muscle and Nerve, 2015, 52, 221-230.	1.0	42
154	Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 2011, 122, 2336-2344.	0.7	40
155	Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. Palliative Medicine, 2016, 30, 471-478.	1.3	40
156	Exploring the Evolution of Cortical Excitability Following Acute Stroke. Neurorehabilitation and Neural Repair, 2016, 30, 244-257.	1.4	40
157	Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 486-495.	1.7	40
158	Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1250-1258.	0.9	39
159	ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology, 2020, 94, e1657-e1663.	1.5	39
160	Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clinical Neurophysiology, 2006, 117, 992-999.	0.7	38
161	The Pathophysiology of Oxaliplatin-Induced Neurotoxicity. Current Medicinal Chemistry, 2006, 13, 2901-2907.	1.2	38
162	Semantic deficits in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 46-53.	1.1	38

#	Article	IF	Citations
163	Engaging in patient decision-making in multidisciplinary care for amyotrophic lateral sclerosis: the views of health professionals. Patient Preference and Adherence, 2012, 6, 691.	0.8	37
164	Neurofascinâ€155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. Muscle and Nerve, 2018, 57, 848-851.	1.0	37
165	Adaptation of motor function after spinal cord injury: novel insights into spinal shock. Brain, 2011, 134, 495-505.	3.7	36
166	Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 2011, 134, 3185-3197.	3.7	35
167	Longitudinal Plasticity Across the Neural Axis in Acute Stroke. Neurorehabilitation and Neural Repair, 2013, 27, 219-229.	1.4	35
168	Axonal Ion Channel Dysfunction inC9orf72Familial Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 49.	4.5	35
169	Primary lateral sclerosis and the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum. Journal of Neurology, 2018, 265, 1819-1828.	1.8	35
170	Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 561-575.	1.0	34
171	Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 184-190.	1.1	34
172	The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 1075-1082.	0.7	34
173	Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. Neuroscience Letters, 2018, 674, 18-23.	1.0	34
174	Has potassium been prematurely discarded as a contributing factor to the development of uraemic neuropathy?. Nephrology Dialysis Transplantation, 2004, 19, 1054-1057.	0.4	33
175	Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 2016, 127, 2355-2361.	0.7	33
176	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open, 2021, 11, e041479.	0.8	33
177	Strength-duration properties of sensory and motor axons in carpal tunnel syndrome. , 1997, 20, 508-510.		32
178	Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle and Nerve, 2014, 50, 894-899.	1.0	32
179	Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 85-92.	1.1	32
180	Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet Journal of Rare Diseases, 2020, 15, 70.	1.2	32

#	Article	IF	Citations
181	Activity-dependent changes in impulse conduction in normal human cutaneous axons. Brain, 1995, 118, 1217-1224.	3.7	31
182	Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care. Health Expectations, 2015, 18, 1769-1782.	1.1	31
183	Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2021, 47, 979-989.	1.8	31
184	Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cerebral Cortex, 2011, 21, 1639-1644.	1.6	30
185	Fasciculation anxiety syndrome in clinicians. Journal of Neurology, 2013, 260, 1743-1747.	1.8	30
186	Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 2013, 36, 1272-1277.	4.3	30
187	Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle and Nerve, 2019, 60, 232-235.	1.0	30
188	Phenotypic variability in ALS-FTD and effect on survival. Neurology, 2020, 94, e2005-e2013.	1.5	30
189	Paraesthesiae Induced by Prolonged high Frequency Stimulation of Human Cutaneous Afferents. Journal of Physiology, 1997, 501, 461-471.	1.3	29
190	Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle and Nerve, 2006, 33, 627-636.	1.0	29
191	Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733.	3.7	29
192	Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 53-59.	1.7	29
193	Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. Annals of Neurology, 2016, 79, 295-305.	2.8	29
194	Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 47-57.	0.9	29
195	The underacknowledged PPA-ALS. Neurology, 2019, 92, e1354-e1366.	1.5	29
196	Consensus for experimental design in electromyography (CEDE) project: Terminology matrix. Journal of Electromyography and Kinesiology, 2021, 59, 102565.	0.7	29
197	Motor neurone disease: progress and challenges. Medical Journal of Australia, 2017, 206, 357-362.	0.8	28
198	Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 2007, 69, 1828-1835.	1.5	27

#	Article	IF	Citations
199	Conduction block and impaired axonal function in tick paralysis. Muscle and Nerve, 2009, 40, 358-362.	1.0	27
200	Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. Journal of Physiology, 2009, 587, 491-504.	1.3	27
201	A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 226-234.	1.1	27
202	Cortical hyperexcitability and the split-hand plus phenomenon: Pathophysiological insights in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 250-256.	1.1	27
203	Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2017, 5, 76.	2.4	27
204	Comparison of crossâ€sectional areas and distalâ€proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 777-783.	1.0	27
205	Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain, 2006, 129, 1585-1592.	3.7	26
206	Ischaemic sensitivity of axons in carpal tunnel syndrome. Journal of the Peripheral Nervous System, 2009, 14, 190-200.	1.4	26
207	Apraxia and Motor Dysfunction in Corticobasal Syndrome. PLoS ONE, 2014, 9, e92944.	1.1	26
208	A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis. Palliative and Supportive Care, 2015, 13, 1019-1024.	0.6	26
209	The Evolution of Caregiver Burden inÂFrontotemporal Dementia with and without Amyotrophic Lateral Sclerosis. Journal of Alzheimer's Disease, 2015, 49, 875-885.	1.2	26
210	Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2015, 126, 828-836.	0.7	26
211	Cerebellar tract alterations in PLS and ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 281-284.	1.1	26
212	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	1.6	26
213	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234.	0.9	26
214	Plasticity of lower limb motor axons after cervical cord injury. Clinical Neurophysiology, 2009, 120, 204-209.	0.7	25
215	Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2015, 2, 1916-1922.	2.7	25
216	Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 2017, 128, 2022-2028.	0.7	25

#	Article	IF	Citations
217	Correlation between markers of peripheral nerve function and structure in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3028.	1.7	25
218	The case of a 48 year-old woman with bizarre and complex delusions. Nature Reviews Neurology, 2010, 6, 175-179.	4.9	24
219	Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 2013, 591, 273-286.	1.3	24
220	Syntactic comprehension deficits across the FTD-ALS continuum. Neurobiology of Aging, 2016, 41, 11-18.	1.5	24
221	Structural and functional papez circuit integrity in amyotrophic lateral sclerosis. Brain Imaging and Behavior, 2018, 12, 1622-1630.	1.1	24
222	Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. Neuroscience Letters, 2021, 759, 136039.	1.0	24
223	Congenital myasthenic syndromes. Journal of Clinical Neuroscience, 2009, 16, 1-11.	0.8	23
224	Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 414-420.	2.3	23
225	Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993.	1.1	23
226	Terra incognitaâ€”cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. Frontiers in Aging Neuroscience, 2015, 7, 121.	1.7	23
227	Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. Journal of Neurophysiology, 2015, 113, 3209-3218.	0.9	23
228	Cortical contributions to the flail leg syndrome: Pathophysiological insights. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 389-396.	1.1	23
229	Cognitive and Behavioral Symptoms in ALSFTD. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 3-10.	1.2	23
230	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	2.9	23
231	Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 2017, 264, 882-890.	1.8	23
232	In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis. Journal of Physiology, 2018, 596, 5379-5396.	1.3	23
233	Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1141.	1.1	23
234	Cortical excitability differences in hand muscles follow a splitâ€hand pattern in healthy controls. Muscle and Nerve, 2014, 49, 836-844.	1.0	22

#	Article	IF	Citations
235	Motor cortical dysfunction develops in spinocerebellar ataxia type 3. Clinical Neurophysiology, 2016, 127, 3418-3424.	0.7	22
236	Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1147-1154.	1.4	22
237	Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. Clinical Neurophysiology, 2016, 127, 911-918.	0.7	22
238	Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 532-537.	1.1	22
239	Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. Journal of Pain, 2020, 21, 44-58.	0.7	22
240	Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices. Clinical Neurophysiology, 2020, 131, 958-966.	0.7	22
241	Consensus for experimental design in electromyography (CEDE) project: High-density surface electromyography matrix. Journal of Electromyography and Kinesiology, 2022, 64, 102656.	0.7	22
242	Motor neurone disease: a Pandora's box. Medical Journal of Australia, 2003, 178, 311-312.	0.8	21
243	Axonal excitability properties in hemifacial spasm. Movement Disorders, 2007, 22, 1293-1298.	2.2	21
244	Changes in human sensory axonal excitability induced by an ischaemic insult. Clinical Neurophysiology, 2008, 119, 2054-2063.	0.7	21
245	Oxaliplatin-Induced Lhermitteâ€™s Phenomenon as a Manifestation of Severe Generalized Neurotoxicity. Oncology, 2009, 77, 342-348.	0.9	21
246	Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 218, 1-4.	2.0	21
247	Hyperexcitability and amyotrophic lateral sclerosis. Neurology, 2012, 78, 1544-1545.	1.5	21
248	Botulinum toxin modulates cortical maladaptation in postâ€stroke spasticity. Muscle and Nerve, 2013, 48, 93-99.	1.0	21
249	Chemotherapy and peripheral neuropathy. Neurological Sciences, 2021, 42, 4109-4121.	0.9	21
250	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain, 2022, 145, 1207-1210.	3.7	21
251	Corticomotoneuronal function in asymptomatic SOD-1 mutation carriers. Clinical Neurophysiology, 2010, 121, 1781-1785.	0.7	20
252	Progress towards therapy in motor neuron disease. Nature Reviews Neurology, 2018, 14, 65-66.	4.9	20

#	Article	IF	Citations
253	The burden of apathy for caregivers of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 599-605.	1.1	20
254	Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 2149-2154.	0.7	20
255	Paradox of amyotrophic lateral sclerosis and energy metabolism. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1013-1014.	0.9	20
256	TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology, 2019, 93, e1748-e1755.	1.5	20
257	Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. Npj Genomic Medicine, 2020, 5, 32.	1.7	20
258	Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. Journal of Cancer Survivorship, 2023, 17, 222-236.	1.5	20
259	The pain with platinum: Oxaliplatin and neuropathy. European Journal of Cancer, 2007, 43, 2631-2633.	1.3	19
260	Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 1373-1382.	1.7	19
261	Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Supportive Care in Cancer, 2020, 28, 4459-4466.	1.0	19
262	The 10-metre gait speed as a functional biomarker in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2010, 11, 558-561.	2.3	18
263	Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 2011, 227, 120-127.	2.0	18
264	Is there a case for diaphragm pacing for amyotrophic lateral sclerosis patients?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 521-527.	2.3	18
265	Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity. Journal of Visualized Experiments, 2012, , .	0.2	18
266	In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain, 2012, 135, 3144-3152.	3.7	18
267	Physiology and pathophysiology of myelinated nerve fibers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 43-53.	1.0	18
268	Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. PLoS ONE, 2013, 8, e59055.	1.1	18
269	Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999.	1.7	18
270	Ischemic resistance of cutaneous afferents and motor axons in patients with amyotrophic lateral sclerosis. , 1998, 21, 1692-1700.		17

#	Article	IF	Citations
271	Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease. , 2005, , 113-129.		17
272	Axonal function in a family with episodic ataxia type 2 due to a novel mutation. Journal of Neurology, 2008, 255, 750-755.	1.8	17
273	Acute, Reversible Axonal Energy Failure During Stroke-Like Episodes in MELAS. Pediatrics, 2010, 126, e734-e739.	1.0	17
274	Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. Muscle and Nerve, 2011, 44, 402-409.	1.0	17
275	In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. Clinical Neurophysiology, 2016, 127, 1700-1706.	0.7	17
276	The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes, 2017, 66, 1661-1670.	0.3	17
277	Amyotrophic lateral sclerosis diagnostic index. Neurology, 2019, 92, e536-e547.	1.5	17
278	The effect of coil type and limb dominance in the assessment of lower-limb motor cortex excitability using TMS. Neuroscience Letters, 2019, 699, 84-90.	1.0	17
279	Behavioural changes predict poorer survival in amyotrophic lateral sclerosis. Brain and Cognition, 2021, 150, 105710.	0.8	17
280	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	3.7	17
281	Motor Cortex Excitability in Acute Cerebellar Infarct. Cerebellum, 2013, 12, 826-834.	1.4	16
282	Precise correlation between structural and electrophysiological disturbances in MADSAM neuropathy. Neuromuscular Disorders, 2015, 25, 904-907.	0.3	16
283	Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218.	1.6	16
284	The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. Journal of Cancer Survivorship, 2022, 16, 223-232.	1.5	16
285	Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537.	1.0	16
286	Tackling clinical heterogeneity across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum using a transdiagnostic approach. Brain Communications, 2021, 3, fcab257.	1.5	16
287	Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis. IDrugs: the Investigational Drugs Journal, 2010, 13, 911-20.	0.7	16
288	Establishment of an Australian motor neurone disease registry. Medical Journal of Australia, 2006, 184, 367-368.	0.8	15

#	Article	IF	Citations
289	Corticomotoneuronal Integrity and Adaptation in Spinal Muscular Atrophy. Archives of Neurology, 2012, 69, 467.	4.9	15
290	Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. Clinical Neurophysiology, 2017, 128, 281-286.	0.7	15
291	Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 974-980.	0.7	15
292	Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169.	0.7	15
293	Potassium control in chronic kidney disease: implications for neuromuscular function. Internal Medicine Journal, 2019, 49, 817-825.	0.5	15
294	Activityâ€dependent conduction failure: molecular insights. Journal of the Peripheral Nervous System, 2011, 16, 159-168.	1.4	14
295	Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2014, 49, 858-865.	1.0	14
296	Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342.	2.0	14
297	Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2015, 31, 175-182.	1.7	14
298	Dissociation of Structural and Functional Integrities of the Motor System in Amyotrophic Lateral		

#	Article	IF	Citations
307	Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. Muscle and Nerve, 2010, 42, 288-292.	1.0	13
308	Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. Clinical Neurophysiology, 2015, 126, 1288-1294.	0.7	13
309	Dynamic muscle ultrasound identifies upper motor neuron involvement in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 404-410.	1.1	13
310	Tracking small sensory nerve action potentials in human axonal excitability studies. Journal of Neuroscience Methods, 2018, 298, 45-53.	1.3	13
311	Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. Clinical Neurophysiology, 2019, 130, 2088-2095.	0.7	13
312	Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 396-402.	1.1	13
313	Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs, 2021, 35, 483-505.	2.7	13
314	Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383.	1.0	13
315	Predicting a Positive Response to Intravenous Immunoglobulin in Isolated Lower Motor Neuron Syndromes. PLoS ONE, 2011, 6, e27041.	1.1	13
316	Appearance, phenomenology and diagnostic utility of the split hand in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2011, 1, 457-462.	1.2	12
317	Implications of structural and functional brain changes in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2018, 18, 407-419.	1.4	12
318	Interrogating interneurone function using threshold tracking of the H reflex in healthy subjects and patients with motor neurone disease. Clinical Neurophysiology, 2020, 131, 1986-1996.	0.7	12
319	Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathyâ€”a randomised controlled trial. Supportive Care in Cancer, 2021, 29, 1103-1110.	1.0	12
320	Pathophysiological associations of transcallosal dysfunction in ALS. European Journal of Neurology, 2021, 28, 1172-1180.	1.7	12
321	Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis. Scientific Reports, 2021, 11, 2172.	1.6	12
322	Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. Oncologist, 2021, 26, 366-374.	1.9	12
323	Apathy is associated with parietal cortical-subcortical dysfunction in ALS. Cortex, 2021, 145, 341-349.	1.1	12
324	Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. Neurology, 2021, 96, e2090-e2097.	1.5	12

#	Article	IF	Citations
325	Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. Genome Medicine, 2022, 14, 7.	3.6	12
326	Riluzole: a glimmer of hope in the treatment of motor neurone disease. Medical Journal of Australia, 2005, 182, 319-320.	0.8	11
327	Treatment approaches in motor neurone disease. Current Opinion in Neurology, 2016, 29, 581-591.	1.8	11
328	Diaphragm ultrasound in amyotrophic lateral sclerosis and other neuromuscular disorders. Clinical Neurophysiology, 2016, 127, 28-30.	0.7	11
329	Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 570-575.	0.9	11
330	Interneuronal networks mediate cortical inhibition and facilitation. Clinical Neurophysiology, 2020, 131, 1000-1010.	0.7	11
331	Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALSâ€FTD spectrum. Annals of Clinical and Translational Neurology, 2021, 8, 1576-1591.	1.7	11
332	Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17.	1.1	11
333	Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 14-23.	1.1	11
334	Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. Quality of Life Research, 2022, 31, 3091-3107.	1.5	11
335	Activity-induced weakness in recessive myotonia congenita with a novel (696+1G>A) mutation. Clinical Neurophysiology, 2006, 117, 2064-2068.	0.7	10
336	TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2016, 366, 197-201.	0.3	10
337	Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2636-2642.	0.7	10
338	Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 2017, 55, 424-427.	1.0	10
339	Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. Clinical Neurophysiology, 2017, 128, 93-99.	0.7	10
340	Motor neurone disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 345-357.	1.0	10
341	CNS cell typeâ€“specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162.	1.6	10
342	Neural networks associated with body composition in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1707-1717.	1.7	10

#	Article	IF	Citations
343	Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1365-1375.	2.2	10
344	Monomelic amyotrophy: non progressive atrophy of the upper limb. Journal of Clinical Neuroscience, 1999, 6, 353-355.	0.8	9
345	Early saccades in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 294-301.	1.1	9
346	Transynaptic Changes Evident in Peripheral Axonal Function After Acute Cerebellar Infarct. Cerebellum, 2014, 13, 669-676.	1.4	9
347	The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 481-482.	0.9	9
348	Peripheral nerve axonal excitability studies: expanding the neurophysiologistâ€™s armamentarium. Cerebellum and Ataxias, 2015, 2, 4.	1.9	9
349	Palliative care in amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 347-348.	4.9	9
350	Cortical function and corticomotoneuronal adaptation in monomelic amyotrophy. Clinical Neurophysiology, 2017, 128, 1488-1495.	0.7	9
351	Excitability of sensory axons in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1472-1478.	0.7	9
352	Effects of hemodialysis on intraneural blood flow in endâ€stage kidney disease. Muscle and Nerve, 2018, 57, 287-293.	1.0	9
353	A unified model of the excitability of mouse sensory and motor axons. Journal of the Peripheral Nervous System, 2018, 23, 159-173.	1.4	9
354	Predictors of survival in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 425-433.	0.9	9
355	Biomarkers and Future Targets for Development in Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 2014, 21, 3535-3550.	1.2	9
356	Threshold electrotonus and the assessment of nerve excitability in amyotrophic lateral sclerosis. Handbook of Clinical Neurophysiology, 2004, 4, 359-366.	0.0	8
357	Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. Journal of Physiology, 2009, 587, 3759-3760.	1.3	8
358	Neuroprotection for Oxaliplatin-Induced Neurotoxicity: What Happened to Objective Assessment?. Journal of Clinical Oncology, 2011, 29, e553-e554.	0.8	8
359	Nerve Excitability. , 2012, , 345-365.		8
360	Impaired energyâ€dependent processes underlie acute lead neuropathy. Muscle and Nerve, 2012, 46, 954-956.	1.0	8

#	Article	IF	Citations
361	ALS and neuromuscular disease: in search of the Holy Grail. Lancet Neurology, The, 2014, 13, 13-14.	4.9	8
362	Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 721-725.	1.0	8
363	Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. American Journal of Pathology, 2018, 188, 1447-1456.	1.9	8
364	Inherited Neuropathies. Seminars in Neurology, 2019, 39, 620-639.	0.5	8
365	Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 162-171.	0.9	8
366	Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Immunology, 2021, 12, 701550.	2.2	8
367	Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 2011, 122, 194-198.	0.7	7
368	Amyotrophic lateral sclerosis and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 355-355.	0.9	7
369	Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. Muscle and Nerve, 2016, 54, 58-64.	1.0	7
370	Review Article â€œSpotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Dateâ€• International Journal of General Medicine, 2021, Volume 14, 4579-4604.	0.8	7
371	Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for caregiver intervention. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 434-441.	1.1	7
372	Normal axonal ion channel function in large peripheral nerve fibers following chronic ciguatera sensitization. Muscle and Nerve, 2008, 37, 403-405.	1.0	6
373	Clarifying variability of corticomotoneuronal function in kennedy disease. Muscle and Nerve, 2011, 44, 197-201.	1.0	6
374	A unique account of ALS in China: exploring ethnic heterogeneity. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1051-1052.	0.9	6
375	Emergence of an imaging biomarker for amyotrophic lateral sclerosis: is the end point near?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 569-569.	0.9	6
376	Prognostic factors in C9orf72 amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.2-281.	0.9	6
377	Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology, 2018, 129, 670-671.	0.7	6
378	Amyotrophic lateral sclerosis: a new diagnostic paradigm. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 903-904.	0.9	6

#	Article	IF	Citations
379	Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 2192-2199.	1.7	6
380	Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 101, 297.e9-297.e11.	1.5	6
381	Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. Frontiers in Neurology, 2021, 12, 743688.	1.1	6
382	Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets. Pharmaceuticals, 2022, 15, 433.	1.7	6
383	Thalamic and Cerebellar Regional Involvement across the ALSâ€“FTD Spectrum and the Effect of C9orf72. Brain Sciences, 2022, 12, 336.	1.1	6
384	Changes in axonal excitability and burst pattern behaviour in synkinesis. Journal of Clinical Neuroscience, 2008, 15, 1288-1290.	0.8	5
385	Emergence of a Predictive Clinical Biomarker for Diabetic Neuropathy. Diabetes, 2012, 61, 1346-1347.	0.3	5
386	When more is needed: The utility of the frontotemporal dementia scale in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 169-171.	1.1	5
387	Lou Gehrig and the ALS split hand. Neurology, 2015, 85, 1995-1995.	1.5	5
388	Progressive bilateral facial weakness. Practical Neurology, 2015, 15, 76-79.	0.5	5
389	Sensory and motor axons are different: implications for neurological disease. Annals of Clinical Neurophysiology, 2017, 19, 3.	0.1	5
390	Effect of racial background on motor cortical function as measured by threshold tracking transcranial magnetic stimulation. Journal of Neurophysiology, 2021, 126, 840-844.	0.9	5
391	Cytoplasmic body myopathy masquerading as motor neuron disease. Muscle and Nerve, 2004, 30, 667-672.	1.0	4
392	Kinnier Wilsonâ€™s puzzling features of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 657-666.	0.9	4
393	Neural correlates of fat preference in frontotemporal dementia: translating insights from the obesity literature. Annals of Clinical and Translational Neurology, 2021, 8, 1318-1329.	1.7	4
394	MiNDALS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328.	1.1	4
395	A Systematic Review of Caregiver Coping Strategies in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 763-777.	1.2	4
396	Measuring change in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1169-1170.	0.9	3

#	Article	IF	Citations
397	Stimulus, response and excitability â€“ What is new?. Clinical Neurophysiology, 2018, 129, 333-334.	0.7	3
398	The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. Cancer Chemotherapy and Pharmacology, 2011, 67, 1189-1190.	1.1	2
399	Apparent anticipation in SOD1 familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 452-456.	1.1	2
400	Acute bulbar, neck and limb weakness with monospecific antiâ€GT1a antibody: A rare localized subtype of Guillainâ€BarrÃ© sydnrome. Muscle and Nerve, 2016, 53, 143-146.	1.0	2
401	Some do not like it hot. Journal of Physiology, 2017, 595, 3251-3252.	1.3	2
402	Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 2018, 57, 615-621.	1.0	2
403	Frontostriatal grey matter atrophy in amyotrophic lateral sclerosis A visual rating study. Dementia E Neuropsychologia, 2018, 12, 388-393.	0.3	2
404	Fasciculation anxiety syndrome in clinicians: FASICS. Practical Neurology, 2020, 20, 433-434.	0.5	2
405	Illness Cognitions in ALS: New Insights Into Clinical Management of Behavioural Symptoms. Frontiers in Neurology, 2021, 12, 740693.	1.1	2
406	Differences in nerve excitability properties across upper limb sensory and motor axons. Clinical Neurophysiology, 2022, 136, 138-149.	0.7	2
407	Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 2022, 30, 5965-5974.	1.0	2
408	A robust framework for characterising diffusion metrics of the median and ulnar nerves: Exploiting stateâ€ofâ€theâ€art tracking methods. Journal of the Peripheral Nervous System, 2022, 27, 67-83.	1.4	2
409	Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN). Clinical Neurophysiology, 2022, 140, 228-238.	0.7	2
410	Paraspinal muscles and amyotrophic lateral sclerosis â€“ Getting to the core?. Clinical Neurophysiology, 2008, 119, 1457-1458.	0.7	1
411	Theme 11 Cognitive and psychological assessment and support. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 301-308.	1.1	1
412	Metabolomic insights into neurodegeneÂrative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1250-1250.	0.9	1
413	Treating adults with spinal muscular atrophy with nusinersen. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1139-1139.	0.9	1
414	A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin. Muscle and Nerve, 2020, 62, E44-E45.	1.0	1

#	Article	IF	Citations
415	Neurology and clinical neurophysiology: an artificial divide. Practical Neurology, 2021, 21, 274-275.	0.5	1
416	Transcranial magnetic stimulation in the cortical exploration of dementia. , 2020, , 327-343.		1
417	Chapter 23 Pathophysiology of paraesthesiae. Supplements To Clinical Neurophysiology, 2002, 54, 156-162.	2.1	0
418	Chemotherapy-Induced Neurotoxicity. , 2010, , 99-119.		0
419	Response to Karam et al.. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 159-160.	2.3	0
420	Tragic choices. Journal of Medical Ethics, 2015, 41, 950-951.	1.0	0
421	Natural history and the dawning of a new era for familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 95-96.	0.9	0
422	Motor neuron disease with malignancy: Clinical and pathophysiological insights. Clinical Neurophysiology, 2019, 130, 1557-1561.	0.7	0
423	009â€…Axonal excitability properties in dravetâ€™s syndrome reflect effect of loss of sodium channels. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A4.1-A4.	0.9	0
424	Neurotoxicity and ALS: Insights into Pathogenesis. , 2021, , 1-19.		0
425	Author Response: Phenotypic Variability in ALS-FTD and Effect on Survival. Neurology, 2021, 96, 1103-1104.	1.5	0
426	Impulse Conduction. , 2003, , 639-642.		0
427	Neurotoxicity and ALS: Insights into Pathogenesis. , 2014, , 1435-1456.		0
428	Functional Characterisation of a GWAS Risk Locus Identifies GPX3 as a Lead Candidate Gene in ALS. SSRN Electronic Journal, 0, , .	0.4	0
429	Schizotypal traits across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum: pathomechanistic insights. Journal of Neurology, 2022, , 1.	1.8	0